PRECISION Study Published in ESMO Open Highlights Utility of Guardant360® Liquid and Guardant Reveal® to Assess Recurrence Risk After Surgery for Colorectal Cancer Metastases
Business Wire•10/11/2026•16:05 ET
0
Key Highlights
- ➤Two-year recurrence-free survival ranged from 78% to 9% across combined-risk groups
- ➤Guardant360 Liquid detected genomic alterations in 97% of eligible patients
- ➤Guardant Reveal detected postoperative MRD in 31% of evaluable patients
- ➤Both adverse features produced a 4.7-fold higher recurrence-or-death hazard
- ➤PRECISION enrolled 130 patients undergoing curative-intent surgery for colorectal metastases
Expert Statements
Shin Kobayashi, MD, PhD, Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East
“The application of ctDNA analysis has evolved dramatically in this decade. However, the clinical utility of preoperative CGP and postoperative MRD testing for guiding perioperative treatment decisions for resectable colorectal oligometastases (CRM) has been unclear.”
Shin Kobayashi, MD, PhD, Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East
“PRECISION suggests that combining pretreatment tumor genomic profiling with postoperative MRD assessment may provide complementary prognostic information. This could help patients and their care teams better understand the post-surgery risk of recurrence and inform the future development of more personalized treatment strategies, although these findings should be prospectively verified in an interventional study.”
Helmy Eltoukhy, chairman and co-CEO of Guardant Health
“These findings illustrate how Guardant’s liquid biopsy tests can provide a comprehensive view of cancer—informing meaningful outcomes that can benefit clinical practice. The study also affirms our commitment to supporting patients throughout the care continuum.”
PRECISION Study Published in ESMO Open Highlights Utility of Guardant360(®) Liquid and Guardant Reveal(®) to Assess Recurrence Risk After Surgery for Colorectal Cancer Metastases
* Combining pretreatment genomic profiling and postoperative molecular residual disease (MRD) testing identified patient groups with estimated two-year recurrence-free survival ranging from 78% to 9%
Get started
Create a free account to read the full story.